GEN Exclusives

More »

The Lists

More »
Dec 18, 2012

Top 20 Venture Capital Firms

Who invests the most funds in the most biotech companies?

Top 20 Venture Capital Firms

These firms have invested the most venture capital or other equity in early- to late-stage biotechnology and pharma companies. [Bobby4237 - Fotolia.com]

  • #10. Domain Associates

    Location(s): Princeton, NJ, and San Diego

    Fund size and status: $2.5 billion under management across eight funds. Current fund: $500 million Domain Partners VIII, closed 2009

    Biopharma portfolio companies: Achaogen, Achillion Pharmaceuticals, Adynxx, Afferent Pharmaceuticals, Alimera Sciences, Applied Proteomics, Ariosa Diagnostics, Ascenta Therapeutics, Asmacure, Astute Medical, aTyr Pharma, BioNano Genomics, Cadence Pharmaceuticals, Celator Pharmaceuticals, Clovis Oncology, CoDa Therapeutics, CoLucid Pharmaceuticals, Corridor Pharmaceuticals, Dicerna Pharmaceuticals, DRI Holdings, Durata Therapeutics, Eddingpharm International Holdings, Epic Sciences, Esperion Therapeutics, Evoke Pharma, Five Prime Therapeutics, IntegenX, Marinus Pharmaceuticals, Meritage Pharma, Neuron Systems, Novadigm Therapeutics, Ocera Therapeutics, Oraya Therapeutics, Orexigen Therapeutics, Otonomy, ParinGenix, ProteinSimple, Regardo Biosciences, Sera Prognostics, Sonexa Therapeutics, Syndax Pharmaceuticals, Tobira Therapeutics, Tragara Pharmaceuticals, VentiRx Pharmaceuticals, Veracyte, Zogenix

    Typical investment range: Investment average or range per-company unavailable

    Year established: 1985

  • #9. Atlas Venture

    Location(s): Cambridge, MA

    Fund size and status: More than $2.5 billion in committed capital across eight funds; raising funds for ninth fund, Atlas Venture IX. Expected to be similar to $283 million current fund, Atlas Venture VIII, closed 2009

    Biopharma portfolio companies: Achilion Pharmaceuticals, Annovation Biopharma, ARCA Biopharma, Arteaus Therapeutics, Bicycle Therapeutics, Egalet, F-star, Horizon Pharma, Infacare Pharmaceutical, JenaValve, MiRagen Therapeutics, Nimbus Discovery, ProtAffin Biotechnologies, RaNA Therapeutics, SciClone Pharmaceuticals, Vitae Pharmaceuticals, Zafgen

    Typical investment range: $500,000 to $5 million

    Year established: 1986

  • #8. MPM Capital

    Location(s): Boston; South San Francisco, CA; Munich; Gainesville, FL; Kansas City, KS

    Fund size and status: About $2.6 billion committed capital under management across five funds. Current fund: Approximately $300 million MPM BioVentures V L.P., closed 2010

    Biopharma portfolio companies: Aires Pharmaceuticals, Allozyne, Anthera Pharmaceuticals, Aveo Pharmaceuticals, Celladon, Ceregene, Chiasma, Colucid Pharmaceuticals, Conatus Pharmaceuticals, EKR Holdings, Epigenomics, Epizyme, Idenix Pharmaceuticals, iPierian, Kalidex, KaloBios Pharmaceuticals, Macrogenics, NeuroTherapeutics Pharma, Oxagen, Pacira Pharmaceuticals, Pharmathene, Poniard Pharmaceuticals, Portola Pharmaceuticals, Proteon Therapeutics, QuatRx Pharmaceuticals, Radius Health, Rhythm Pharmaceuticals, Solasia Pharma, Somaxon Pharmaceuticals1

    Typical investment range: Investment average or range per-company unavailable

    Year established: 1996

  • #7. InterWest Partners

    Location(s): Menlo Park, CA

    Fund size and status: $2.8 billion under management across 10 funds. Current fund: $650 million IW X Fund, closed 2008

    Biopharma portfolio companies: Applied Genetic Technologies (AGTC), Alvine Pharmaceuticals, Amplimmune, APT Pharmaceuticals, Arcion Therapeutics, Biomimetic, Carbylan Biosurgery, Cebix, Drais Pharmaceuticals, Eiger Pharmaceuticals, Follica, Fluidigm, Glaukos, Lycera, Integrated Diagnostics, Ocera Therapeutics, On Demand Therapeutics, PrimeraDx, QuatRx Pharmaceuticals, RadioRx, Satori Pharmaceuticals, Sera Prognostics, Tesaro, Transcept Pharmaceuticals, Trius Therapeutics, USDS, Xenon Pharmaceuticals

    Typical investment range: $10 million to $15 million

    Year established: 1979

  • #6. Polaris Venture Partners

    Location(s): Waltham, MA; New York; Palo Alto, CA; and Dublin

    Fund size and status: More than $3 billion under management across six funds. Current fund: $375 million Polaris Venture Partners VI, closed 2010

    Biopharma portfolio companies: 480 Biomedical, Acceleron Pharma, Adimab, Alimera Sciences, Arsanis Biosciences, Arsenal Medical, aTyr Pharma, BIND Biosciences, Calorics Pharmaceuticals, Cerulean Pharma, deCODE Genetics [to be acquired by Amgen for $415 million], Fate Therapeutics, Genocea Biosciences, Hydra Biosciences, Ironwood, Kala Pharmaceuticals, Promedior, Pulmatrix, Receptos, Xtuit Pharmaceuticals

    Typical investment range: Investment average or range per-company unavailable

    Year established: 1996

  • #5. Kleiner Perkins Caufield & Byers

    Location(s): Menlo Park, CA; San Francisco; Beijing; Shanghai

    Fund size and status: More than $3 billion in assets under management across 15 funds. Current fund: $525 million KPCB 15, closed May 2012

    Biopharma portfolio companies: 3-V Biosciences, Alphavax, Apnicure, Arresto Biosciences, Athena Neurosciences, Auxogyn, BioCryst Pharmaceuticals, Biosite, CardioDx, Cardium Therapeutics, Celladon, Corixa, Corthera, Crescendo Bioscience, Elcelyx, Epizyme, FivePrime Therapeutics, Focal, Foundation Medicine, Gen-Probe, Genomic Health, iPierian, ITC, Microcide Pharmaceuticals, Navigenics, Neurocrine Biosciences, Nexus Dx, Nodality, NovaDigm Therapeutics, Novavax, Onyx Pharmaceuticals, Orexigen, Pacific Biosciences, Pharmacopeia, Pharmacyclics, Tesaro, Tethys, Trius Therapeutics, Veracyte

    Typical investment range: Seed investments typically range from $100,000 to $1 million; early-stage, from $1 million to $10 million; growth-stage, from $10 million to $75 million

    Year established: 1972

  • #4. Highland Capital Partners

    Location(s): Cambridge, MA; Menlo Park, CA; Geneva; London; and Shanghai

    Fund size and status: $3.337 billion under management across nine funds; raising funds for 10th fund, Highland Capital Partners IX L.P. Expected to be similar to $400 million Highland Capital Partners VIII L.P., closed 2009.

    Biopharma portfolio companies: Aveo Pharmaceuticals, iPierian, Opgen, Predictive Biosciences

    Typical investment range: Investment average or range per-company unavailable

    Year established: 1988

  • #3. Canaan Partners

    Location(s): Menlo Park, CA; Westport, CT; New York; Gurgaon, India; Herzliya Pituach, Israel

    Fund size and status: $3.4 billion under management across nine funds. Current fund: $600 million Canaan Partners IX, closed January 2012

    Biopharma portfolio companies: Adlyfe, ALDEA Pharmaceuticals, Amicus Therapeutics, Apieron, Centocor, Chimerix, Civitas Therapeutics, CombinatoRx, Cylex, CytomX Therapeutics, Data Sciences International, Dermira, DexCom, Durata Therapeutics, GenVec, Kalidex Pharmaceuticals, Liquidia Technologies, Marinus Pharmaceuticals, Matrix Pharma, Novira Therapeutics, Phylogix, Pozen, Sopherion, Theraclone Sciences, Tobira Therapeutics, VaxInnate

    Typical investment range: Investment average or range per-company unavailable

    Year established: 1987

  • #2. OrbiMed Advisors

    Location(s): New York; San Francisco; Shanghai; Mumbai; Herzliya, Israel

    Fund size and status: About $6 billion under management in four public funds, as well as private equity funds in North America/Europe, Asia, and Israel; and a Royalty Opportunities Fund launched 2011 to fund life sciences companies

    Biopharma portfolio companies: Acceleron Pharma, Adimab, Affimed, Amarin, Ambit Biosciences, Aragon Pharmaceuticals, arGEN-X, Arsanis Biosciences, Arteaus, Bharat Serums and Vaccines, Biodel, Cardioxyl, cCAM Biotherapeutics, Cerenis Therapeutics, Cleave Biosciences, Eddingpharm, Good Start Genetics, Igenica, Intercept Pharmaceuticals, MacroGenics, MethylGene, Otic Pharma, Pacira Pharmaceuticals, PharmAbcine, Pieris AG, Principia Biopharma, Puma Biotechnology, RDD Pharma, Receptos, Relypsa, Rempex Pharmaceuticals, Response BioMedical, Roka Bioscience, Selecta Biosciences, Shasun, Singulex, Supernus Pharmaceuticals

    Typical investment range: Investment average or range per-company unavailable

    Year established: 1989

  • #1. New Enterprise Associates (NEA)

    Location(s): Menlo Park, CA; Chevy Chase, MD; Timonium, MD; New York, and affiliate operations in Beijing; Shanghai; Bangalore; Mumbai. On Oct. 17, NEA announced plan to open Chicago office

    Fund size and status: More than $13 billion in committed capital across 14 funds. Current fund: $2.6 billion New Enterprise Associates 14 L.P., closed July 2012. Typically, NEA invests 25% to 40% of its funds healthcare companies, including biotechnology

    Biopharma portfolio companies: 3-V Biosciences, Aciex, Amicus Therapeutics, Aradigm, Ardelyx, BrainCells, Cadence Pharmaceuticals, Cardioxyl Pharmaceuticals, Clovis Oncology, Dermira, Epizyme, Galera Therapeutics, GlycoMimetics, Hydra Biosciences, Hyperion Therapeutics, Intarcia Therapeutics, Liquidia Technologies, Mersana Therapeutics, Nexchem, Novast, Omthera Pharmaceuticals, Pharmos, PhaseBio, Predictive Biosciences, Prosensa, Proteostasis Therapeutics, Psyadon Pharmaceuticals, Ra Pharma, Rhythm, Roka Bioscience, Satori Pharmaceuticals, Sunesis, Supernus Pharmaceuticals, Targacept, Tesaro, Theravance, Transcept Pharmaceuticals, Trevena, Vitae Pharmaceuticals, Zosano Pharma, Zyngenia

    Typical investment range: $5 million to $50 million per company

    Year established: 1978


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Tackling Climate Change

Do you think most companies will respond positively to the People’s Climate March?